Core Viewpoint - Li Auto reported a revenue of 112.3 billion yuan and a net profit of 1.1 billion yuan for the fourth quarter and the entire year of 2025, marking it as the only new force car company in China to achieve over 100 billion yuan in revenue and profitability for three consecutive years [1] Financial Performance - Revenue for 2025 reached 112.3 billion yuan, with a net profit of 1.1 billion yuan [1] - Cash reserves at the end of 2025 amounted to 101.2 billion yuan, the highest among Chinese electric vehicle companies [1] - R&D investment for the year was 11.3 billion yuan, a historical high, with 50% allocated to AI-related projects [1][3] Strategic Transition - 2025 is identified as a critical year for the company's transformation from an automotive enterprise to an embodied intelligence enterprise, with significant progress in restructuring the entire operational chain [1] - The company has focused on addressing operational pain points in its direct sales system to facilitate growth [1] R&D and Technological Advancements - Li Auto's R&D investment over the past three years totaled 33 billion yuan, averaging 1 billion yuan spent every three days, emphasizing a commitment to breakthroughs in embodied intelligence core technologies [3][5] - The self-developed Mach 100 chip is set to begin mass production in Q2 2025, offering three times the effective computing power of Nvidia's Thor-U chip [5] - The company has established a full-stack self-research capability in chips, compilers, operating systems, and foundational models, enhancing its ability to customize AI computing power [5] Product Development - The new generation Li Auto L9 Livis, priced at 559,800 yuan, is set to launch in Q2 2025, representing a significant upgrade in user experience and targeting the high-end market [6][8] - The L9 Livis features advanced 3D perception systems and is equipped with two self-developed Mach 100 chips, providing 5 to 6 times the computing power of competing chips [8] - The company aims to leverage its existing product recognition to drive growth through both extended-range and pure electric vehicles, with cumulative orders for the i6 and i8 surpassing 100,000 units [8][9] Future Outlook - The company is positioned to return to a growth trajectory in 2026, with a focus on realizing three years of technological accumulation [9] - The launch of the new generation L9, equipped with the Mach 100 chip, is expected to enhance the company's technological framework and mission to create better products and services for users [9]

3月13日，滴滴在其官网发布2025年第四季度及全年业绩报告。公司四季度稳中有升，为2025年全 年稳健经营画上句点。四季度，滴滴核心平台（中国出行与国际业务）订单量同比增长13.5%至48.44亿 单，单日订单峰值超6500万单。2025年全年，核心平台订单量达到182.4亿单，同比增长14%。 单量的提升带来交易规模的扩大。四季度，滴滴核心平台交易额（GTV）同比增长19.9%至1238亿 元；2025全年核心平台总交易额（GTV）同比增长14.8%至4508亿元。 另一方面，持续探索推出新服务，提升用户出行体验，进而提升用户粘性。四季度，滴滴核心会员 数对比去年同期上涨超过15%。滴滴会员目前已陆续上线20余项权益，包括打车权益、场站权益，以及 联合希尔顿、华住会、海底捞、亚朵、海南航空等打通跨界会员权益互通，构建起"地面出行+空中出 行+餐饮住宿"的全链路会员福利体系。 此外，通过提升技术能力、完善指引标识和服务设施等方式，滴滴目前已在全国165个城市的313座 机场、火车站，包括北京首都国际机场、深圳湾口岸、杭州东站等进行体验升级。 滴滴创始人、CEO程维表示：第四季度中国出行和国际业务单量再创新高 ...

念, @人民日报 今起，2026年研考初试成绩陆续公布。愿你的努力都有回报！ ...

2月27日，深交所发布"十四五"、启航"十五五"概述。 概述指出，"十四五"时期，深交所深入贯彻党中央、国务院决策部署，认真落实中国证监会和驻证监会 纪检监察组工作要求，一体推进防风险、强监管、促高质量发展，突出强本强基、严监严管，增强制度 包容性、适应性，实现市场功能"六大提升"，助力中国式现代化新征程迈出稳健步伐。 亮点数据方面，截至"十四五"末，深市ETF产品规模合计1.79万亿元，较"十四五"初期增长8倍。其 中，"创业板系列"ETF总规模2823亿元，债券ETF规模2266亿元，分别增长3倍和36倍。 深港通迎来9周年，保持平稳运行，"十四五"累计成交110万亿元，较"十三五"增长3.5倍，深股通、港股 通标的数量分别达到1825只和588只，标的市值占比均接近90%，可交易标的越来越多，可交易时间越 来越长，跨境交易便利度越来越高。 高水平开放是资本市场高质量发展的必由之路。"十四五"时期，深交所稳步扩大高水平制度型对外开 放，助力畅通国内国际双循环。互联互通让投资更便捷。深港通迎来9周年，保持平稳运行，"十四 五"累计成交110万亿元，较"十三五"增长3.5倍，深股通、港股通标的数量分别达到18 ...

当地时间2月27日，美国国家航空航天局（NASA）局长艾萨克曼宣布对"阿尔忒弥斯"载人登月计划进 行重大调整：将增加一次载人飞船在近地轨道与月球着陆器的对接测试——也就是说，美国原定在"阿 尔忒弥斯3号"任务中完成载人登月，现在要将"阿尔忒弥斯3号"任务改为对接测试，计划于2028年进行 的"阿尔忒弥斯4号"任务才将是载人"重返月球"。而且完成相关任务所需的月球着陆器仍在开发中。 美国于2019年宣布"阿耳忒弥斯"登月计划，并于2022年11月完成"阿耳忒弥斯1号"无人绕月飞行测试任 务。 目前，"阿尔忒弥斯2号"任务，也就是载人绕月飞行，都还没有完成，相关发射时间已被一推再推。 ...

Core Viewpoint - The People's Bank of China (PBOC) has decided to lower the foreign exchange risk reserve requirement for forward foreign exchange sales from 20% to 0% starting March 2, 2026, to promote the development of the foreign exchange market and support enterprises in managing exchange rate risks [1]. Group 1: Policy Changes - The reduction in the foreign exchange risk reserve requirement is aimed at lowering the forward purchase costs for enterprises and increasing their willingness to engage in foreign exchange hedging [1]. - This marks the first use of this tool by the PBOC in nearly three and a half years, indicating a rational exit from previous measures and a return to a neutral foreign exchange policy [1]. Group 2: Impact on Enterprises - The adjustment is expected to help financial institutions provide cost-effective foreign exchange risk management products to enterprises, aligning with a broader policy initiative announced on January 15 [1]. - By 2025, it is anticipated that the hedging ratio for enterprises will increase to 30%, and the proportion of trade settled in RMB will also rise to nearly 30%, suggesting that around 60% of enterprises will be less affected by exchange rate risks in foreign trade [1]. Group 3: Market Conditions - Since the beginning of the year, the RMB has appreciated against the USD by approximately 2%, influenced by a weakening US dollar index [2]. - The PBOC plans to continue guiding financial institutions to optimize exchange rate hedging services for enterprises, aiming to maintain the RMB exchange rate at a reasonable and balanced level [2].

Core Viewpoint - The current performance of bank wealth management products is under pressure due to market volatility, leading to a mismatch between investor return expectations and risk preferences, which is expected to fully manifest by 2026 [1][7]. Group 1: Market Performance and Trends - In January 2026, the bank wealth management market showed minimal growth, as banks focused on loan sales rather than wealth management products [2]. - The decline in market interest rates has made insurance products, particularly dividend insurance, more attractive to investors, leading to a shift away from traditional wealth management products [2][6]. - Investors are increasingly cautious, with some opting for fixed deposits over wealth management products due to recent poor performance [3]. Group 2: Strategies to Attract Investment - Banks are launching special wealth management products, such as "Lantern Festival Exclusive" offerings, to attract customer funds during key financial planning periods [4]. - Many institutions are reducing management and service fees to enhance customer retention and attract new clients, although this strategy is seen as a temporary measure [5][6]. - The industry is exploring two main strategies to improve product returns: extending the duration of investments and diversifying asset allocation [7][8]. Group 3: Challenges and Considerations - The strategy of extending investment duration faces challenges due to narrowing yield spreads and increased sensitivity of product net values to interest rate fluctuations [7]. - Diversifying asset allocation to include equities and convertible bonds is seen as a way to enhance returns, but it requires improved investment capabilities and poses risks of increased net value volatility [8].

同行评议与多轮人工复核流程。针对直接服务临床决策支持的重要内容，引入同行评议和多轮人工复核 流程，重点关注安全边界、禁忌事项和高风险场景，确保内容符合当前医疗行业的专业共识和质量要 求。 近日，中央网信办旗下杂志《中国网信》刊发了丁香园创始人、董事长李天天的署名文章：以 "负责任 创新" 探索医疗人工智能发展新路径。文章提到了丁香园在医疗人工智能领域秉持 "负责任创新" 理 念，在医疗AI产品的研发上以数据质量为优先，坚持 "有错必纠"，强化风险提示与循证依据前置，减 少低级错误发生的概率，谨慎推进医疗人工智能的应用实践。以下为文章全文： 近年来，人工智能技术在医疗健康领域的应用不断深化，从医学知识检索、辅助诊疗到科研支持与健康 管理，展现出广阔前景。与此同时，算法偏差、数据质量、责任边界等问题也逐渐显现。如何在鼓励技 术创新的同时，有效防范潜在风险，推动人工智能在医疗健康领域实现风险可控、结论可信、发展可持 续，成为当前亟须回应的重要课题。在这一背景下，"负责任创新" 逐渐成为行业发展共识。在医疗健 康等高风险领域，更应坚持审慎原则，将安全性、有效性和合规性置于优先位置。 以数据质量为核心的技术路径选择 医 ...

Group 1 - Shanghai Zedman Pharmaceutical Technology Co., Ltd. has signed an agreement with Jichuan Pharmaceutical Co., Ltd. for exclusive commercialization rights of Zeli Mei in China, excluding Hong Kong, Macau, and Taiwan [1] - Zedman will receive a maximum of 190 million yuan in upfront and milestone payments, including a maximum of 125 million yuan upfront and 65 million yuan for research milestones [1] - This collaboration marks a significant milestone in Zedman's market expansion and is a strategic move for resource complementarity and mutual benefits [1] Group 2 - Zeli Mei (Bimodamide Cream) is an innovative non-hormonal drug developed by Zedman, approved for treating eczema in children over 2 years old and adults, representing the first AhR modulator for this indication [2] - The drug works by suppressing inflammation, repairing skin barriers, regulating microbiota, and combating oxidative stress, addressing clinical pain points of traditional treatments [2] - Zedman’s CEO emphasized the importance of this partnership for maximizing the innovative value of Zeli Mei and accelerating its market promotion and clinical application in China [2] Group 3 - Jichuan Pharmaceutical's General Manager highlighted that this collaboration strengthens their product layout in pediatric and dermatological treatments, filling a clinical gap for young patients with eczema [2] - The partnership aims to leverage Jichuan's established sales network and specialized academic promotion team to expedite Zeli Mei's market entry and clinical adoption [2] - This initiative will enhance Jichuan's product matrix in pediatrics and dermatology, contributing to the development of skin health for children and adults in China [2]

Core Viewpoint - The Chinese stock market showed mixed performance with the Shanghai Composite Index slightly up by 0.39%, while the Shenzhen Component Index and the ChiNext Index experienced minor declines [1] Market Performance - The Shanghai Composite Index closed at 4162.88 points with a trading volume of 10,723.68 billion yuan, reflecting a gain of 0.39% [1] - The Shenzhen Component Index closed at 14,495.09 points with a trading volume of 14,156.56 billion yuan, showing a decrease of 0.06% [1] - The ChiNext Index ended at 3,310.31 points with a trading volume of 6,627.59 billion yuan, down by 1.04% [1] Sector Performance - The non-ferrous metals sector continued to strengthen, with companies like Hunan Gold and Zhangyuan Tungsten hitting the daily limit [1] - The power sector maintained its strong performance, with multiple stocks such as Southern Power Grid Energy and Henan Energy Holdings also reaching the daily limit [1] - The computing power leasing concept was active, with stocks like Yuntian Lifu and Tuo Wei Information hitting the daily limit [1] - The CPO and PCB concepts experienced a pullback, with stocks like Xinyi Sheng and Zhongji Xuchuang dropping over 5% [1] - Steel, gas, and coal sectors showed notable gains, while storage chips, fiberglass, and composite copper foil sectors faced declines [1]